replenine-vf, 50 iu/ml human factor ix, a powder for solution.
bio products laboratory limited - factor ix, human - powder for solution for injection - factor ix, human 50 international unit(s)/millilitre - antihemorrhagics
emoclot 500 iu lyophilized powder for injection (iv)
n/a; importer: new marketlink pharmaceutical corporation; distributor: metro drug inc. - human plasma coagulation factor viii - lyophilized powder for injection (iv) - 500 iu
csl singapore monofix-vf human coagulation factor ix freeze dried 500iu powder for injection
csl behring australia pty ltd - factor ix -
wilate 500 500 iu vwf500 iu fviii powder and solvent for solution for injection
pharmaniaga marketing sdn bhd - coagulation factor viii; von willebrand factor -
wilate 1000 1000 iu vwf1000 iu fviii powder and solvent for solution for injection
pharmaniaga marketing sdn bhd - coagulation factor viii; von willebrand factor -
monofix-vf
csl behring (nz) ltd - factor ix 1000 [iu] (100iu/ml when reconstituted with 10ml water for injection) - injection with diluent - 1000 iu - active: factor ix 1000 [iu] (100iu/ml when reconstituted with 10ml water for injection) excipient: antithrombin iii chloride citric acid monohydrate heparin phosphorus plasma protein fraction sodium water for injection - monofix®-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix®-vf is not indicated for the treatment of factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix®-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.
monofix-vf
csl behring (nz) ltd - factor ix 500 [iu] (50 iu/ml when reconstituted with 10 ml water for injections) - injection with diluent - 50 iu/ml - active: factor ix 500 [iu] (50 iu/ml when reconstituted with 10 ml water for injections) excipient: antithrombin iii chloride citric acid monohydrate heparin phosphorus plasma protein fraction sodium water for injection - monofix®-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix®-vf is not indicated for the treatment of factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix®-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.
alphanate 500unit powder and solvent for solution for injection vials
grifols uk ltd - factor viii high purity; von willebrand factor - powder and solvent for solution for injection - 500unit ; 200unit
alphanate 1,000unit powder and solvent for solution for injection vials
grifols uk ltd - factor viii high purity; von willebrand factor - powder and solvent for solution for injection - 1000unit ; 1200unit
wilate 500 powder for solution for i/v injection
octapharma pharmazeutika produktionsges. m.b.h. - human blood coagulation factor viii, human von willebrand factor - powder for solution for i/v injection - 500iu/5ml+ 500iu/5ml